Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib Safety and Activity in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
NCT00531284Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2007
- Primary completion
- Oct 2014
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in solid tumor, multiple myeloma (MM), lymphoma, ovarian cancer, renal cell carcinoma (RCC), sponsored by Amgen. Started Sep 2007; status: completed.
02
Drugs
carfilzomib
03
Conditions
solid tumormultiple myeloma (MM)lymphomaovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00531284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531284.